论文部分内容阅读
近年来,药品回扣问题正日益成为社会关注的热点问题之一,人民群众反应十分强烈。回扣方式层出不穷。“明扣”、“暗扣”甚至还有“扣中扣”,老百姓深受其害。2001年12月1日,我国实施新的《药品管理法》。新修订的《药品管理法》针对我国在药品研究、生产、经营和使用中出现的新情况和新问题,进行了有针对性的修订,对药品流通领域中的暗中交易行为明确了其应负的法律责任,为加强药品监督管理、打击医药回扣提供了法律依据。
In recent years, the issue of drug rebate is increasingly becoming one of the hot issues of concern to the society. The people are very reactionary. Rebate mode after another. “Ming buckle”, “dark buckle” or even “buckle buckle”, people suffer. On December 1, 2001, China implemented the new Drug Administration Law. The newly revised Drug Administration Law has made targeted amendments to new situations and new problems that emerged in the study, production, operation and use of pharmaceuticals in our country and made it clear that they should shoulder the secret transaction in the field of pharmaceutical distribution The legal responsibility, to strengthen drug supervision and management, to combat medical rebates provided the legal basis.